Category: Cancer Treatment

Mikhail Blagosklonny and His Plans for Oncology

Mikhail Blagosklonny, researcher, professor, and philanthropist, has played a significant roll in the study of cancer and again. Mikhail Blagosklonny works as a professor of Oncology at the Roswell Park Cancer Institute in Buffalo, New York. He has headed up major research on the topic of cancer treatments. Mikhail Blagosklonny is also editor-in -Chief for Oncotarget where he has published the results of his extensive research about the natural process of aging.

Arguably, one of his more noteworthy accomplishments is his advocation for the use of Rapaymycin, a cancer drug, for the purpose of lengthening life of humans. This study has been a break through in this field of science, and remains unparalleled in its import to date.

Why all the fanfare regarding the use of Rapaymycin? One reason is because of the immunosupressant qualities of the drug. When an organ transplant occurs, there is danger of rejection of the new organ. If the rejection happens, the transplant fails. To help prevent this from happening, doctors typically prescribe anti-rejection drugs such as calcineurin inhibitors, or immunosuppressant drugs. The downside to the use of these drugs is that over time, they can actually damage the kidneys of the patient. Rapaymycin has a low level of toxicity on the kidneys, therefore reducing the chance of damage.

Another break-though application of the use of Rapaymycin is in the treatment of cancer. When fighting cancer, Sirolimus is commonly recommended because of its antiproliferative properties. Rapaymycin, in proper doses, is able to boost the immune response of the body against tumors. By the same token, tumor regression is also enhanced. By using Rapaymycin, the chances of contracting cancer in transplant patients are decreased.

As a researcher and professor in Oncology, Mikhail Blagosklonny is particularly interested in the connection between cancer and aging, and why cancer is more common in people above a certain age. His goal is not only to figure out the why of when cancer occurs, but also the logistics of treating cancer. He hopes to discover a method of treatment that is not as costly and painful as they are today. Mikhail Blogosklonny wants to find a way to destroy the cancer cells without damaging the healthy cells, which are vitally important in the process of recovery.

In the field of aging, Mikhail Blagosklonny continues with research regarding the effects of Rapaymycin on longevity. So far, the studies have shown that when Rapaymycin is administered before the flu vaccination that there is some immunological rejuvenation in elderly patients. Though the research is still in progress, Mikhail Blagosklonny is hopeful that the drug will lead to increasing a person’s longevity.

Topics that have inspired Mikhail Blagosklonny have attracted attention in the medical field. The progress made has generated interest from many others in his field around the world who will carry on the studies. Mikhail Blagosklonny believes that treatment for cancer will be developed. He also believes that the treatment will not be a luxury, but will be cost-effective and available to everyone.

Dr. David Samadi’s Upcoming Show to Play a Crucial Role in Breast Cancer Awareness

October has become known as the month of Breast Cancer Awareness (BCAM). Major breast cancer charities organize an international health campaign aimed at, among other things, increasing awareness about breast cancer. This year’s campaign gets a boost in form of a show hosted by Dr. David Samadi, Sunday Housecall LIVESTREAM. In a show to be broadcast on October 15, Dr. Samadi will interview Dr. CynaraCoomer. The latter is the Chief of Breast Surgery and Director of the Comprehensive Breast Center at Northwell Health Staten Island University Hospital.

Dr. Cynara has dedicated her honorable career to helping women attain quality life by diagnosing and treating various tumors of the breast such as benign and malignant tumors. She is also passionate about creating awareness of breast cancer as it reduces the stigma associated with the condition as well as early detection which increases the chances of surviving the disease. Dr. Cynara’s lobbying resulted in the establishment of the first Comprehensive Breast Center on Staten Island. Once a colleague of Dr. Samadi at Lennox Hill Hospital, Dr. Cynara is at the forefront of fighting breast cancer, and Dr. Samadi describes her as an “esteemed former colleague.”

Although this Sunday’s show will be all about breast cancer, Dr. Samadi’s other shows will focus on different medical conditions afflicting both men and women as well as emerging trends in medical world. Dr. Samadi’s shows will be live every Sunday starting at 12:30 PM EDT. Interested viewers can stream the live show on Viewers are privileged to either call in or email their questions, strictly on health and wellness, which Dr. Samadi and his guest (s) will answer either during the live show or after the show.

Dr. Samadi’s current show is a culmination of other shows he has hosted. Between 2011 and 2016, he hosted “Sunday Housecall” on Fox News Channel. Beginning in March 2015, he started a radio program, “World Health News,’’ broadcast on New York City’s am970. Dr. Samadi has published numerous medical papers, articles, and journals and his blog and website,, are overflowing with crucial medical information.

A graduate of Stony Brook University, Dr. Samadi went on to attend other universities in the U.S and other countries with interest in specializing in the diagnosis and treatment of prostate cancer. As an expert in urologic diseases, Dr. Samadi stresses the use of minimally invasive treatments procedures of treating prostate cancer. He emigrated to the US from Iran in 1979.

For details:

Clay Siegall; Revolutionizing The Battle Against Cancer

Clay Siegall is the mastermind behind the establishment of Seattle Genetics, a leading pharmaceutical firm that targets the cure of chronic illnesses. Clay has in his possession a degree in Zoology from the University of Maryland as well as a doctorate in Genetics from the George Washington University.


Since the commencement of Seattle Genetics, the company has made revolutionary accomplishments in the targeted remedy industry. The firm recently became the pioneering institution to develop an antibody drug conjugate accredited by the Food and Drug Administration. This invention, along with other that are currently in the works, has earned Seattle Genetics productive partnerships with industry giants such as Pfizer and Bayer.


Furthermore, Seattle Genetics has undergone massive growth, transforming from a novice to a renowned entity. Despite this remarkable achievements, Clay visualizes an even bigger future, with the company becoming a global figure. Siegall also believes that current oncologic procedures such as chemotherapies have their days numbered, as the industry embraces the up and coming targeted therapies which are far more efficient and bearable.


Clay developed an interest in medicine and technology from a tender age. The passion for developing cancer therapy came to him while he was an undergraduate. A close relative of his was a cancer patient, who had chemotherapy administered on him. The effects of the medication were adverse and almost deadly, so Clay embarked on a mission to find a more sustainable alternative. The motivation to have autonomy as well as make money also drove Clay to inaugurate Seattle Genetics.


Seattle Genetics makes money in many ways, among which the primary means is through direct sales of products and services. Also, the company gets a significant proportion of profits from leasing out technologies they pioneered. The company had a tough stat, but everything started to run smoothly after conducting the IPO. At a given period, the company almost went on its knees, as the capital was almost depleted.


The company employs sales staff that are well acquainted with pharmaceutical products and terminologies. For this reason, they have maintained a respectable number of customers in their client base. The institution also ensures that there is a close rapport between them and their clientele.



Cancer Treatment Center of America (CTCA) Unveils a Leading-edge Clinical Pathways, a Customized Platform for Cancer Treatment

Cancer Treatment Centers of America has entered an innovative partnership with Allscripts and NantHealth, which will see the three partners execute a custom technical solution. This technical support solution allows eviti, a cutting-edge NantHealth clinical solution, to acquire information on clinical workflows on the electronic health record of Allscripts Sunrise. The Clinical Pathways program offers information about the cancer treatment procedure, without necessarily interfering with the doctor’s clinical workflow. Hundreds of oncologists based in the U.S. participated in the designing of the clinical operating system’s interface. The system harbors an all-inclusive collection of growing cancer care data.

As stated in the article, “Cancer Treatment Centers of America® Partners with Allscripts and NantHealth to Launch Clinical Pathways, a Comprehensive and Custom Oncology Treatment Platform,” Clinical Pathways avails all correct treatment alternatives. CMO of CTCA, George Daneker, said that the Clinical Pathways assists in the elimination of possible guesswork by physicians. The program incorporates new cancer research, treatment procedures, and alternative therapies into electronic health record (EHR) Allscripts Sunrise.

Benefits of the treatment platform

• Personalized treatment procedures that address the individual needs of patients, their health, as well as definite disease state

• Supported clinical data

Easy access to reliable information on adverse drug rates, response rates, and toxicity

• Instantaneous functionality

What is Cancer Treatment Centers of America?

The Florida-based Cancer Treatment Centers of America (CTCA) is a renowned national, for-profit partnership of five hospitals, which serve cancer patients across the U.S. CTCA approaches cancer treatment in an integrative manner that entails utilization of conventional techniques, such as chemotherapy, immunotherapy, radiation, and surgery, to manage cancer. Additionally, these hospitals provide integrative therapies to minimize side effects, including nausea, malnutrition, anxiety, lymphedema, fatigue, depression, and depression.

After cancer had claimed the life of his mother, Mr. Richard J Stephenson became more focused on finding an effective treatment for the life-threatening disease. He oversaw the launch of the first CTCA hospital back in 1988. Four other health care centers opened their doors from 2005 to 2012.

Supportive Therapies and Treatment Options Set The Cancer Treatment Centers of America Apart From Other Hospitals

Cancer Treatment Centers of America (CTCA) recently announced their adoption of the Clinical Pathways program, a NantHealth technology-based clinical decision support platform that will effectively organize all of the new cancer treatment information available to oncologists. Curated by oncologists, oncology associations, government agencies and more, the program offers information on more than 2,700 treatment options for all types of cancers.

According to Wikipedia, while the Clinical Pathways program makes it easy for oncologists to discuss options with their patients and to order a chemotherapy regimen, the program empowers patients as well. CTCA’s patients are able to view the same information as their oncologist about their available options, including response rates, clinical data, toxicity and more.

Based in Boca Raton, Florida, operates five non-profit hospitals nationwide; in addition, they maintain a presence in the Caribbean, Latin America and the Middle East for individuals interested in visiting one of CTCA’s U.S. locations. CTCA is famous for their integrative approach to cancer treatments, which comprises of chemotherapy and radiation therapy, plus supportive therapies that combat stress, depression, pain and other effects of cancer treatments. Few cancer treatment centers offer the supportive therapies that the CTCA hospitals do, which include acupuncture, mind-body medicine, nutrition therapy and more.

At CTCA, all of the medical professionals specialize in patient-centered cancer care; patients select the latest technologies and therapies available to them after learning about all of their options from the Clinical Pathways program. Patients also enjoy coordinated care where all of their health care providers are located at one hospital.

For further information about CTCA follow them on Facebook.